Estab Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1) | MicrobiomeTrials← Back to trialsNCT03981575
Estab Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1)
RecruitingOBSERVATIONAL
Trial Details
Start: 2019-01-01Est. Completion: 2026-10-01
Enrollment target: 700 participants Locations- University of California, San Diego, La Jolla, California, United States
- University of California, Los Angeles, Los Angeles, California, United States
- University of Colorado - Denver, Denver, Colorado, United States
- University of Florida, Gainesville, Florida, United States
- University of Iowa, Iowa City, Iowa, United States
- Kansas University Medical Center, Kansas City, Kansas, United States
- University of Rochester, Rochester, New York, United States
- Ohio State University, Columbus, Ohio, United States
- Houston Methodist Neurological Institute, Houston, Texas, United States
- Virginia Commonwealth University, Richmond, Virginia, United States
- Université de Sherbrooke, Québec, Canada
- Friedrich Baur Institute, Ludwig-Maximilians-Universität München, München, Germany
- Centro Clinico NeMO, Milan, Italy
- Radboud University Medical Center, Nijmegen, Netherlands
- University of Auckland, Auckland, New Zealand
- St. George's, University of London, London, United Kingdom
Other microbiome trials you might be interested in
Congenital Myotonic DystrophyCDM
The overall goal of the study is to establish valid clinical endpoint assessments for children with congenital myotonic …
Los Angeles, United StatesEst. completion Oct 2026
Advanced Breast Cancer Brain Metastasis
A prospective, multicenter, observational cohort study to evaluate the efficacy and safety of a novel anti-tumor drug as…
Beijing, ChinaEst. completion Sep 10, 2028
University College London, London, United Kingdom